

**Online Supplement for:**

**Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore  
Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects**

Yutaka Saisho<sup>a#</sup>, Takayuki Katsube<sup>b</sup>, Scott White<sup>c\*</sup>, Hiroyuki Fukase<sup>d</sup>, Jingoro Shimada<sup>e</sup>

Medical Affairs Department, Shionogi & Co., Ltd., Osaka, Japan<sup>a</sup>; Clinical Research  
Department, Shionogi & Co., Ltd., Osaka, Japan<sup>b</sup>; Glaxo SmithKline, Philadelphia, PA, USA<sup>c</sup>;  
CPC Clinical Trial Hospital, Kagoshima, Japan<sup>d</sup>; Shionogi & Co., Ltd., Tokyo, Japan<sup>e</sup>

**Running Head:** Pharmacokinetics and Safety of Cefiderocol

#Address correspondence to Yutaka Saisho at [yutaka.saisho@shionogi.co.jp](mailto:yutaka.saisho@shionogi.co.jp)

\*Present address: Scott White, Clinical Development, Inovio Pharmaceuticals, Inc., Plymouth  
Meeting, PA, USA.

**Supplemental Table 1.** Total iron-binding capacity ( $\mu\text{g}/\text{dl}$ ) in the multiple-dose study<sup>a</sup>

		Multiple-Dose Cefiderocol			
Time point	Statistic	1000 mg 1 <sup>st</sup>	1000 mg 2 <sup>nd</sup>	2000 mg	Placebo
		(n=8)	(n=8) <sup>b</sup>	(n=8)	(n=6)
Day 1 (baseline)	Mean (change from baseline)	295.8 (0)	283.1 (0)	281.6 (0)	332.7 (0)
	SD	17.4	51.3	26.5	39.9
	Median	297.0	292.5	278.0	328.5
	Range	268–315	170–346	249–335	281–396
Day 2	Mean (change from baseline)	296.0 (+0.3)	279.0 (-4.1)	294.6 (+13.0)	328.3 (-4.3)
	SD	15.4	52.8	27.7	36.0
	Median	302.0	285.5	287.5	322.5
	Range	266–314	162–339	266–349	280–384
Day 3	Mean (change from baseline)	299.6 (+3.9)	281.0 (-2.1)	291.5 (+9.9)	331.3 (-1.3)
	SD	20.8	49.9	37.2	38.4
	Median	301.5	286.5	278.0	329.0
	Range	255–328	169–336	259–373	282–398
Day 5	Mean (change from baseline)	295.6 (-0.1)	273.1 (-10.0)	290.1 (+8.5)	338.7 (+6.0)
	SD	23.3	47.3	35.3	30.2
	Median	302.0	279.5	285.5	328.0
	Range	249–317	170–334	245–358	304–379
Day 8	Mean (change from baseline)	303.1 (+7.4)	271.8 (-11.4)	290.0 (+8.4)	335.8 (+3.2)
	SD	24.2	47.1	33.9	26.1
	Median	307.0	284.0	286.5	330.0
	Range	255–334	168–317	246–353	312–386
Day 10	Mean (change from baseline)	291.4 (-4.4)	287.4 (-11.9)	277.8 (-3.9)	321.8 (-10.8)
	SD	25.4	22.1	35.4	28.6

	Median	294.5	276.0	271.0	312.5
	Range	248–322	265–321	234–354	296–376
Day 11	Mean (change from baseline)	296.9 (+1.1)	291.7 (-7.6)	289.4 (+7.8)	333.2 (+0.5)
	SD	25.1	23.8	41.1	26.5
	Median	299.5	287.0	280.0	330.5
	Range	249–324	260–327	242–375	308–382
Day 12	Mean (change from baseline)	303.8 (+8.0)	301.1 (+1.9)	298.3 (+16.6)	334.5 (+1.8)
	SD	21.4	17.6	47.1	28.9
	Median	303.0	300.0	291.0	330.5
	Range	270–337	281–329	250–385	309–388
Day 13	Mean (change from baseline)	296.1 (+0.4)	310.1 (+10.9)	297.6 (+16.0)	330.5 (-2.2)
	SD	33.0	29.0	42.7	29.5
	Median	285.5	310.0	293.5	323.5
	Range	248–337	274–361	256–378	305–387
Day 14	Mean (change from baseline)	290.8 (-5.0)	290.0 (-9.3)	292.1 (+10.5)	323.5 (-9.2)
	SD	26.1	27.6	31.3	25.7
	Median	285.5	294.0	289.0	314.5
	Range	252–333	260–332	255–341	296–367
Day 17	Mean (change from baseline)	277.6 (-18.1)	291.7 (-7.6)	289.8 (+8.1)	314.7 (-18.0)
	SD	23.6	27.2	28.5	25.2
	Median	287.5	283.0	283.0	314.5
	Range	240–297	260–326	268–356	281–353

---

<sup>a</sup>Reference range: 290–355 µg/dl.

<sup>b</sup>n=7 for days 10, 11, 12, 14, and 17.